NCT03432741 - Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

August 26, 2022

Study Completion Date

October 3, 2022

Conditions

Breast AdenocarcinomaMetastatic Breast CarcinomaRecurrent Breast CarcinomaRecurrent Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Breast CarcinomaRefractory Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Nodal Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG

Belinostat

Given intralesionally

DRUG

Carfilzomib

Given intralesionally

DRUG

Copanlisib Hydrochloride

Given intralesionally

BIOLOGICAL

Daratumumab

Given intralesionally

DRUG

Fludeoxyglucose F-18

Undergo FDG-PET

DRUG

Gemcitabine Hydrochloride

Given intralesionally

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given intralesionally

BIOLOGICAL

Obinutuzumab

Given intralesionally

BIOLOGICAL

Pembrolizumab

Given intralesionally

PROCEDURE

Positron Emission Tomography

Undergo FDG-PET

BIOLOGICAL

Rituximab

Given intralesionally

DRUG

Romidepsin

Given intralesionally

OTHER

Saline

Given intralesionally

BIOLOGICAL

Trastuzumab

Given intralesionally

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester